ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

2025.02.17
Minimal residual disease (MRD) is a powerful predictor of relapse in acute myeloid leukemia (AML), yet its accuracy remains a challenge. Some patients who are MRD-positive do not relapse, while others who are MRD-negative still experience disease recurrence. At the 2024 American Society of Hematology (ASH) Annual Meeting, Professor Jerald Radich from Fred Hutchinson Cancer Center provided an in-depth analysis of how mutations, clonal architecture, and disease evolution influence treatment response, resistance, and relapse.To clarify the complex relationship between MRD and clonal dynamics, Hematology Frontier has compiled key insights from this discussion.
Case Compilation | The Battle of Outstanding Clinical Cases

Case Compilation | The Battle of Outstanding Clinical Cases

2025.02.17
Lung cancer remains the most common and deadliest malignancy in China. Optimizing treatment strategies is essential for extending patient survival and improving quality of life. In the era of precision medicine, targeted therapies such as icotinib and befotertinib have provided significant breakthroughs for non-small cell lung cancer (NSCLC), demonstrating the commitment and innovation of Chinese pharmaceutical companies in the global fight against cancer.
SABCS 2024: Insights on Anthracyclines in High-Risk HR+/HER2- Breast Cancer

SABCS 2024: Insights on Anthracyclines in High-Risk HR+/HER2- Breast Cancer

2025.02.17
At SABCS 2024, Nan Chen, MD, presented insights from a post-hoc analysis of TAILORx, exploring the role of anthracyclines in high genomic risk, node-negative HR+/HER2- breast cancer. The discussion focused on how Recurrence Score (RS) > 31 may influence treatment decisions and the potential impact of tumor size on chemotherapy benefits. These insights challenge prior assumptions about anthracycline use in HR+ breast cancer and highlight the need for a more personalized approach in high-risk patients.
OlympiA Trial 10-Year Update: Major Findings from SABCS 2024

OlympiA Trial 10-Year Update: Major Findings from SABCS 2024

2025.02.17
At SABCS 2024, Dr. Judy Garber presented the latest 10-year follow-up results from the OlympiA trial, which continue to reinforce the role of adjuvant olaparib in patients with germline BRCA1/2 mutation-associated, high-risk HER2-negative breast cancer. With a median follow-up of 6.1 years (maximum 9.6 years), the trial confirms the long-term benefits of olaparib in reducing recurrence and improving survival outcomes.
ILCA 2024丨Dr. Tao Peng: New Therapy for Early Multinodular Liver Cancer — Promising Results from Cadonilimab Combined with FOLFOX-HAIC

ILCA 2024丨Dr. Tao Peng: New Therapy for Early Multinodular Liver Cancer — Promising Results from Cadonilimab Combined with FOLFOX-HAIC

2025.02.17
Editor’s Note: Primary hepatocellular carcinoma (HCC) is a prevalent malignant tumor, and combining systemic therapy, immunotherapy, and regional local treatment is guiding HCC clinical treatment to new heights. At the recent 18th International Liver Cancer Association (ILCA) Annual Meeting, Dr. Tao Peng from the Hepatobiliary Surgery Department of The First Affiliated Hospital of Guangxi Medical University shared findings from a preliminary clinical trial targeting multinodular HCC. This study explored the use of cadonilimab (Cadonilimab) combined with the FOLFOX regimen via hepatic artery infusion chemotherapy (HAIC) as a neoadjuvant treatment, aimed at providing a more effective treatment strategy for resectable multinodular HCC patients. Oncology Frontier invited Dr. Tao Peng to discuss the main findings and clinical significance of the study.